Literature DB >> 23867993

APRIL depletion induces cell cycle arrest and apoptosis through blocking TGF-β1/ERK signaling pathway in human colorectal cancer cells.

Feng Wang1, Lin Chen, Hongbin Ni, Guihua Wang, Weifeng Ding, Hui Cong, Shaoqing Ju, Shumei Yang, Huimin Wang.   

Abstract

It is well documented that a proliferation-inducing ligand (APRIL), a newly found member of tumor necrosis factor superfamily, overexpressed in the majority of malignancies, plays a potential role in the occurrence and development of these tumors. Herein, we demonstrated that APRIL depletion by using RNA interference in human colorectal cancer (CRC) COLO 205 and SW480 cells resulted in cell proliferation inhibition and evoked cell cycle arrest in G0/G1 phase and apoptosis, coupled with decrease in CDK2, Cyclin D1, Bcl-2 expression and an increase of p21 and Bax expression. In addition, the decreased expression of transforming growth factor-β1 (TGF-β1) and p-ERK was also showed in siRNA-APRIL transfected COLO 205 and SW480 cells, whereas the protein expression levels of Smad2/3, p-Smad2/3, and ERK were not significantly changed. Taken together, our results indicate that APRIL depletion induces cell cycle arrest and apoptosis partly through blocking noncanonical TGF-β1/ERK, rather than canonical TGF-β1/Smad2/3, signaling pathway in CRC cells. Moreover, our study highlights APRIL as a potential molecular target for the therapy of CRC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23867993     DOI: 10.1007/s11010-013-1766-8

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  37 in total

1.  The TNF family member APRIL promotes colorectal tumorigenesis.

Authors:  V Lascano; L F Zabalegui; K Cameron; M Guadagnoli; M Jansen; M Burggraaf; M Versloot; H Rodermond; C van der Loos; C E Carvalho-Pinto; H Kalthoff; J P Medema; M Hahne
Journal:  Cell Death Differ       Date:  2012-06-15       Impact factor: 15.828

2.  AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal-to-epithelial transdifferentiation by inhibiting TGF-β-mediated ERK signaling.

Authors:  B Kong; C W Michalski; X Hong; N Valkovskaya; S Rieder; I Abiatari; S Streit; M Erkan; I Esposito; H Friess; J Kleeff
Journal:  Oncogene       Date:  2010-06-28       Impact factor: 9.867

Review 3.  TGF-β signalling and its role in cancer progression and metastasis.

Authors:  Yvette Drabsch; Peter ten Dijke
Journal:  Cancer Metastasis Rev       Date:  2012-12       Impact factor: 9.264

4.  APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status.

Authors:  John Quinn; Janet Glassford; Laura Percy; Philippa Munson; Teresa Marafioti; Manuel Rodriguez-Justo; Kwee Yong
Journal:  Blood       Date:  2010-08-13       Impact factor: 22.113

Review 5.  TGF-β1 signalling, connecting aberrant inflammation and colorectal tumorigenesis.

Authors:  Victoria R Skeen; Ian Paterson; Christos Paraskeva; Ann C Williams
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 6.  Tgf-beta signaling alterations and colon cancer.

Authors:  Naresh Bellam; Boris Pasche
Journal:  Cancer Treat Res       Date:  2010

7.  APRIL knockdown suppresses migration and invasion of human colon carcinoma cells.

Authors:  Weifeng Ding; Jinchun Wang; Baolan Sun; Shaoqing Ju; Hongxiang Yuan; Xing Wang; Yueguo Wang; Huimin Wang
Journal:  Clin Biochem       Date:  2009-06-30       Impact factor: 3.281

8.  A proliferation-inducing ligand: a new biomarker for non-small cell lung cancer.

Authors:  Baolan Sun; Huimin Wang; Xing Wang; Hua Huang; Weifeng Ding; Rongrong Jing; Gongsheng Shi; Li Zhu
Journal:  Exp Lung Res       Date:  2009-08       Impact factor: 2.459

9.  A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth.

Authors:  P Rennert; P Schneider; T G Cachero; J Thompson; L Trabach; S Hertig; N Holler; F Qian; C Mullen; K Strauch; J L Browning; C Ambrose; J Tschopp
Journal:  J Exp Med       Date:  2000-12-04       Impact factor: 14.307

10.  APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth.

Authors:  M Hahne; T Kataoka; M Schröter; K Hofmann; M Irmler; J L Bodmer; P Schneider; T Bornand; N Holler; L E French; B Sordat; D Rimoldi; J Tschopp
Journal:  J Exp Med       Date:  1998-09-21       Impact factor: 14.307

View more
  6 in total

1.  Tumor necrosis factor superfamily member 13 is a novel biomarker for diagnosis and prognosis and promotes cancer cell proliferation in laryngeal squamous cell carcinoma.

Authors:  Ru Wang; Yichao Guo; Hongzhi Ma; Lin Feng; Qi Wang; Xiaohong Chen; Meng Lian; Haizhou Wang; Jugao Fang
Journal:  Tumour Biol       Date:  2015-09-23

2.  miR-383 inhibits hepatocellular carcinoma cell proliferation via targeting APRIL.

Authors:  Lin Chen; Haitao Guan; Chunyan Gu; Yali Cao; Jianguo Shao; Feng Wang
Journal:  Tumour Biol       Date:  2015-09-18

3.  Identification of the sAPRIL binding peptide and its growth inhibition effects in the colorectal cancer cells.

Authors:  Xiao-qing He; Jing Guan; Fang Liu; Jing Li; Mei-rong He
Journal:  PLoS One       Date:  2015-03-31       Impact factor: 3.240

4.  The role of ZFP580, a novel zinc finger protein, in TGF-mediated cytoprotection against chemical hypoxia‑induced apoptosis in H9c2 cardiac myocytes.

Authors:  Shi-Yun Mao; Xiang-Yan Meng; Zhong-Wei Xu; Wen-Cheng Zhang; Xiao-Han Jin; Xi Chen; Xin Zhou; Yu-Ming Li; Rui-Cheng Xu
Journal:  Mol Med Rep       Date:  2017-02-22       Impact factor: 2.952

5.  Synergisic effect of APRIL knockdown and Jiedu Xiaozheng Yin, a Chinese medicinal recipe, on the inhibition of hepatocellular carcinoma cell proliferation.

Authors:  Zhizhen Liu; Lianming Liao; Zhiyun Cao; Xuzheng Chen; Jian Du
Journal:  Oncol Rep       Date:  2016-12-28       Impact factor: 3.906

6.  Global, Survival, and Apoptotic Transcriptome during Mouse and Human Early Embryonic Development.

Authors:  D Haouzi; I Boumela; K Chebli; S Hamamah
Journal:  Biomed Res Int       Date:  2018-11-01       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.